# Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

> **NCT06369610** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 110 (estimated)

## Conditions studied

- Oligometastatic Prostate Carcinoma
- Prostate Adenocarcinoma

## Interventions

- **DRUG:** Abiraterone Acetate
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Gonadotropin-releasing Hormone Analog
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Questionnaire Administration
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT06369610
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-22
- **Primary completion:** 2027-04-22
- **Final completion:** 2027-04-22
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06369610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06369610, "Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06369610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*